Breaking News

Tekmira Licenses Marina Biotech’s RNAi Technology

To develop therapeutics that silence disease-causing genes

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Tekmira Pharmaceuticals has obtained a worldwide, non-exclusive license to a novel RNAi payload technology, Unlocked Nucleobase Analog (UNA), from Marina Biotech. The UNA technology will be used for the development of RNAi therapeutics to treat disease by silencing specific disease causing genes. Marina will receive an upfront payment plus milestone and royalty payments on products developed by Tekmira that use UNA technology. Financial terms were not disclosed.   “Our license to Marina&#8...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters